June 26, 2013

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (AB-55)	BOCOCIZUMAB
PRONUNCIATION	boe" koe siz' ue mab
THERAPEUTIC CLAIM	Treatment of dyslipidemia

CHEMICAL NAME

1. Immunoglobulin G2, anti-(human neural apoptosis-regulated proteinase 1)(human-Mus musculus monoclonal PF-04950615 heavy chain), disulfide with human-Mus musculus monoclonal PF-04950615 light chain, dimer

2. Immunoglobulin G2-kappa, anti-[human proprotein convertase subtilisin/hexin type 9 (neural apoptosis-regulated convertase 1, PC9)], humanized mouse monoclonal antibody; gamma 2 heavy chain (1-444) [humanized VH (*Homo sapiens* IGHV1-46-1*03 (90.8%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118)-*Homo sapiens* IGHG2*01 CH2A^{100}>S(327),CH2P^{101}>S(328) (119-444)] (132-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (88.2%)-IGKJ2*01 [6.3.9] (1'-107')-IGKC*01 (108'-214')]; dimer (220-220'':221-221'':224-224'':227-227'')-tetrakisdisulfide

STRUCTURAL FORMULA

Heavy chain

QVQLVQSGAE	VKKPGASVKV	SCKASGYTFT	SYYMHWVRQA	PGQGLEWMGE	50
ISPFGGRTNY	NEKFKSRVTM	TRDTSTSTVY	MELSSLRSED	TAVYYCARER	100
PLYASDLWGQ	GTTVTVSSAS	TKGPSVFPLA	PCSRSTSEST	AALGCLVKDY	150
FPEPVTVSWN	SGALTSGVHT	FPAVLQSSGL	YSLSSVVTVP	SSNFGTQTYT	200
CNVDHKPSNT	KVDKTVERKC	CVECPPCPAP	PVAGPSVFLF	PPKPKDTLMI	250
SRTPEVTCVV	VDVSHEDPEV	QFNWYVDGVE	VHNAKTKPRE	EQFNSTFRVV	300
SVLTVVHQDW	LNGKEYKCKV	SNKGLPSSIE	KTISKTKGQP	REPQVYTLPP	350
SREEMTKNQV	SLTCLVKGFY	PSDIAVEWES	NGQPENNYKT	TPPMLDSDGS	400
FFLYSKLTVD	KSRWQQGNVF	SCSVMHEALH	NHYTQKSLSL	SPGK	444

Light chain

DIQMTQSPSS	LSASVGDRVT	ITCRASQGIS	SALAWYQQKP	GKAPKLLIYS	50'
ASYRYTGVPS	RFSGSGSGTD	FTFTISSLQP	EDIATYYCQQ	RYSLWRTFGQ	100'
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYSLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges location

22-96	22"-96"	23'-88'	23'"-88"'	132-214'	132"-214"'
134'-194'	134"'-194"'	145-201	145"-201"	220-220"	221-221"
224-224"	227-227"	258-318	258"-318"	364-422	364"-422"

Modified residues

E
1, 1"
pyroglutamic acid (Glp)



Glycosylation sites (N)

Asn-294 Asn-294"

MOLECULAR FORMULA	$C_{6414}H_{9918}N_{1722}O_{2012}S_{54}$
MOLECULAR WEIGHT	145.1 kDa
TRADEMARK	None as yet
SPONSOR	Pfizer, Inc.
CODE DESIGNATIONS	RN316, PF-04950615
CAS REGISTRY NUMBER	1407495-02-6
WHO NUMBER	9840

gbk